Clinical usefulness of fecal calprotectin for ulcerative colitis

Clinical usefulness of fecal calprotectin for ulcerative colitis - Triple-C study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017650

Enrollment

2000

Registered

2015-05-22

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients who were diagnosed as UC 2 Patients who were/will be conducted colonoscopy 3 Informed consent was obtained prior to clinical study 4 Patients whose age are equal to/more than 18 years -old. In addition clinical remission is obtained in case of entry for investigation of clinical outcome

Exclusion criteria

Exclusion criteria: Patients who received total colectomy Patients who received bowel resection within 6 months prior to entry of this study Patients who have recent GI bleeding, infectious colitis or colonic adenocarcinoma. Patients who received leukocyte or granulocyte- monocyte apheresis therapy. Patients who received non-steroid anti-inflammatory agent (NSAID).

Design outcomes

Primary

Measure	Time frame
To evaluate relation between fecal calprotectin/fecal occult blood test and endoscopic severity To evaluate usefulness of fecal calprotectin/fecal occult blood test on long-term prognosis of UC	—

Countries

Japan

Contacts

Public ContactMakoto Naganuma

School of Medicine, Keio University Division of Gastroenterology and Hepatoligy

nagamakoto@z7.keio.ac.jp03-3353-1211

Outcome results